Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
HEALTHSTREAM INC
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-52.6% vs price
Base Case (Median)
-43.4% vs price
Bull Case (75th pct.)
-1.5% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $44.71 | 29.3% | High (40%) |
| PE Comparable | $18.80 | -45.7% | Medium (25%) |
| Growth Trajectory DCF | $19.58 | -43.4% | Medium (20%) |
| Graham Number | $14.01 | -59.5% | Low (10%) |
| EV/EBITDA | $23.45 | -32.2% | Medium (20%) |
| EV/FCF | $48.41 | 40.0% | Medium (20%) |
| Earnings Power Value | $8.68 | -74.9% | Medium (50%) |
Based on 7 out of 7 methods, HSTM appears overvalued at the current price of $34.59. The base case fair value of $19.58 implies 43.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.